In vitro to human in Vivo translation - Pharmacokinetics and pharmacodynamics of quinidine

Altex

Volumn 30, Issue 3, 2013, Pages 309-318

  Polak, Sebastian ^a,b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b CERTARA UK LIMITED   (United Kingdom)

Author keywords

Drug cardiotoxicity; IVIVE; Modeling and simulation; Quinidine

Indexed keywords

QUINIDINE;

ARTICLE; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG METABOLISM; DRUG TRANSPORT; HEART; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PHARMACODYNAMICS; PHARMACOKINETICS; PREDICTION;

EID: 84883867728     PISSN: 1868596X     EISSN: 18688551     Source Type: Journal    
DOI: 10.14573/altex.2013.3.309     Document Type: Article

References (34)

1. Belz, G. G., Aust, P. E., Doering, W., et al. (1982). Pharmacodynamics of a single dose of quinidine during chronic digoxin treatment. Eur J Clin Pharmacol 22, 117-122.
2. Ching, M. S., Elliott, S. L., Stead, C. K., et al. (1991). Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole. Aliment Pharmacol Ther 5, 523-531.
3. Darbar, D., Fromm, M. F., Dellorto, S., and Roden, D. M. (2001). Sympathetic activation enhances QTprolongation by quinidine. J Cardiovasc Electrophysiol 12, 9-14.
4. El-Eraky, H. and Thomas, S. H. (2003). Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine. Br J Clin Pharmacol 56, 198-204.
5. Fieldman, A., Beebe, R. D., and Sing Sum Chow, M. (1977). The effect of quinidine sulfate on QRS duration and QTand systolic time intervals in man. J Clin Pharmacol 17, 134-139.
6. Glinka, A. and Polak, S. (2012). Wild type and K897T polymorphisms of the hERG gene: modeling the AP in Caucasians. Bioinformation 8, 1062-1065.
7. ICH 2005). International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. The Non-Clinical Evaluation of The Potential for Delayed Ventricular Repolarization (QTInterval Prolongation) by Human Pharmaceuticals S7B http://www fda.gov/ RegulatoryInformation/Guidances/ucm129121.htm
8. Kang, J., Chen, X. L., Wang, L., and Rampe, D. (2001). Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG. J Pharmacol Exp Ther 299, 290-296.
9. Kaukonen, K. M., Olkkola, K. T., and Neuvonen, P. J. (1997). Itraconazole increases plasma concentrations of quinidine. Clin Pharmacol Ther 62, 510-517.
10. Kirsch, G. E., Trepakova, E. S., Brimecombe, J. C., et al. (2004). Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Meth 50, 93-101.
11. Laganiere, S., Davies, R. F., Carignan, G., et al. (1996). Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. Clin Pharmacol Ther 60, 255-264.
12. Lalonde, R. L., Kowalski, K. G., Hutmacher, M. M., et al. (2007). Model-based drug development state of the art. Clin Pharmacol Ther 82, 21-32.
13. Marshall, S., Macintyre, F., James, I., et al. (2006). Role of mechanistically-based pharmacokinetic/pharmacodynamic models in drug development: a case study of a therapeutic protein. Clin Pharmacokinet 45, 177-197.
14. Michel, D., Wegener, J. W., and Nawrath, H. (2002). Effects of quinine and quinidine on the transient outward and on the L-type Ca(2+) current in rat ventricular cardiomyocytes. Pharmacology 65, 187-192.
15. Min, D. I., Ku, Y. M., Geraets, D. R., and Lee, H. (1996). Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers. J Clin Pharmacol 36, 469-476.
16. Mirams, G. R., Cui, Y., Sher, A., et al. (2011). Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc Res 91, 53-61.
17. Niederer, S. A., Fink, M., Noble, D., and Smith, N. P. (2009). A meta-analysis of cardiac electrophysiology computational models. Exp Physiol 94, 486-495.
18. O'Hara, T. and Rudy, Y. (2011). Arrhythmia formation in subclinical ("silent") long QTsyndrome requires multiple insults: quantitative mechanistic study using the KCNQ1 mutation Q357R as example. Heart Rhythm 9, 275-282.
19. Olatunde, A. and Price Evans, D. A. (1982). Blood quinidine levels and cardiac effects in white British and Nigerian subjects. Br J Clin Pharmacol 14, 513-518.
20. Polak, S. and Fijorek, K. (2012). Inter-individual variability in the pre-clinical drug cardiotoxic safety assessment - analysis of the age - cardiomyocytes electric capacitance dependence. J Cardiovasc Transl Res 5, 321-332.
21. Polak, S., Wisniowska, B., Ahamadi, M., and Mendyk, A. (2011). Prediction of the hERG potassium channel inhibition potential with use of Artificial Neural Networks. App Soft Comp 11, 2611-2617.
22. Polak, S., Wisniowska, B., Fijorek, K., et al. (2012a). ToxComp - in vitro-in vivo extrapolation system for the drugs proarrhythmic potency assessment. Comput Cardiol 39, 789-793.
23. Polak, S., Fijorek, K., Glinka, A., et al. (2012b). Virtual population generator for human cardiomyocytes parameters. In silico drug cardiotoxicity assessment. Toxicol Mech Methods 22, 31-40.
24. Polak, S., Wisniowska, B., Glinka A., et al. (2012c). Slow delayed rectifying potassium current (IKs) - analysis of the in vitro inhibition data and predictive model development. J Appl Toxicol Feb 14. doi: 10.1002/jat.2719.
25. Polak, S., Wisniowska, B., Glinka, A. and Polak, M. (2012d). tox-database.net - data describing the chemicals triggered in vitro cardiac ionic channels inhibition. BMC Pharmacol Toxicol 2012, 13.
26. Rescigno, A. (1992). Bioequivalence. Pharm Res 9, 925-928.
27. Rostami-Hodjegan, A. and Tucker, G. T. (2007). Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6, 140-148.
28. Sennels, H. P., Jorgensen, H. L., Goetze, J. P., and Fahrenkrug, J. (2012). Rhythmic 24-hour variations of frequently used clinical biochemical parameters in healthy young males - The Bispebjerg study of diurnal variations. Scand J Clin Lab Invest 72, 287-295.
29. Shin, J. G., Kang, W. K., Shon, J. H., et al. (2007). Possible interethnic differences in quinidine-induced QTprolongation between healthy Caucasian and Korean subjects. Br J Clin Pharmacol 63, 206-215.
30. Sjodie;gren, A. L. (1971). Left ventricular wall thickness determined by ultrasound in 100 subjects without heart disease. Chest 60, 341-346.
31. ten Tusscher, K. H., Noble, D., Noble, P. J., and Panfilov, A. V. (2004). A model for human ventricular tissue. Am J Physiol Heart Circ Physiol 286, H1573-H1589.
32. Wisniowska, B., Mendyk, A., Fijorek, K., et al. (2012). Predictive model for the L-type channel inhibition - multichannel block in QTprolongation risk assessment. J Appl Toxicol 32, 858-866.
33. Woolf, S. H. (2008). The meaning of translational research and why it matters. JAMA 299, 211-213.
34. Zerhouni, E. A. (2005). Translational and clinical science - time for a new vision. N Engl J Med 353, 1621-1623.